Evidence map›Paper›PMID 36143025›Full record

ArticleJournal of clinical medicine2022

Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation-A Phase I Study.

Christian Rausch, Ulrike Bacher, Manuela Rabaglio, Corinne Vorburger, Anke Klingenberg, Yara Banz, Michael Daskalakis, Thomas Pabst

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Christian RauschDepartment of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, 3010 Bern, Switzerland.
Ulrike BacherDepartment of Hematology, Inselspital, University Hospital Bern, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0001-8771-947X
Manuela RabaglioDepartment of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0002-6764-1844
Corinne VorburgerDepartment of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, 3010 Bern, Switzerland.
Anke KlingenbergDepartment of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, 3010 Bern, Switzerland.
Yara BanzInstitute of Pathology, University of Bern, 3008 Bern, Switzerland.
Michael DaskalakisDepartment of Hematology, Inselspital, University Hospital Bern, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0002-8138-0505
Thomas PabstDepartment of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0002-6055-5257
University of Bern · CH

Funding

Takeda Global, Takeda Switzerland Clinical TAKEDA IISR Study Grant Activation (IISR-2014-100841, X25034)
6 · The paper itself

Abstract

The prognosis for patients with CD30+ lymphomas (Hodgkin lymphoma and various T-cell lymphomas) relapsing after autologous stem cell transplantation (ASCT) is critical. Brentuximab vedotin (BV), an ADC targeting CD30, is an obvious candidate for inclusion into high-dose chemotherapy (HDCT) regimens to improve outcomes. This single center phase I trial investigated 12 patients with CD30+ lymphoma (AITL:

Indexed as

angioimmunoblastic T-cell lymphoma (AITL)autologous stem cell transplantation (ASCT)brentuximab vedotin (BV)CD30 lymphomaHodgkin

Identifiers

PMID36143025
PMCPMC9503567
OpenAlexW4296004284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.